CN Patent

CN102626522A — 基于趋化因子受体cxcr4多肽类拮抗剂的多肽放射性诊断与治疗药物

Assigned to Individual · Expires 2012-08-08 · 14y expired

What this patent protects

本发明提供了一种基于趋化因子受体CXCR4多肽类拮抗剂的多肽放射性诊断与治疗药物，所述多肽含cyclo(D-Tyr 1 -P 2 -Arg 3 -2-NaI 4 -Gly 5 ，其中P可为-Orn、-Lys、-(N-Me)Orn、-(N-Me)Lys或者为其D型异构体)序列，其具有分子靶向趋化因子受体CXCR4的功能，可用于艾滋病、恶性肿瘤、肺纤维化、关节炎及干细胞治疗领域的诊断和治疗。

USPTO Abstract

本发明提供了一种基于趋化因子受体CXCR4多肽类拮抗剂的多肽放射性诊断与治疗药物，所述多肽含cyclo(D-Tyr 1 -P 2 -Arg 3 -2-NaI 4 -Gly 5 ，其中P可为-Orn、-Lys、-(N-Me)Orn、-(N-Me)Lys或者为其D型异构体)序列，其具有分子靶向趋化因子受体CXCR4的功能，可用于艾滋病、恶性肿瘤、肺纤维化、关节炎及干细胞治疗领域的诊断和治疗。

Drugs covered by this patent

Patent Metadata

Patent number
CN102626522A
Jurisdiction
CN
Classification
—
Expires
2012-08-08
Drug substance claim
No
Drug product claim
No
Assignee
Individual
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.